Literature DB >> 8608682

Anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome.

V Pengo1, A Biasiolo, M Grazia Fior, A Ruffatti.   

Abstract

Autoimmune antiphospholipid antibodies are a hallmark of patients with antiphospholipid syndrome, and require a protein cofactor, beta 2-glycoprotein I, to bind anionic phospholipids. In these same patients, moreover, IgG directly binding beta 2-glycoprotein I are described. We found high plasma titres of both IgM and IgG anti beta 2-glycoprotein I antibodies in a patient with catastrophic antiphospholipid syndrome. After passing plasma through a Sephacryl S-300 column, an identical distribution pattern between anti beta 2- glycoprotein I and anticardiolipin antibodies was observed. Moreover, when IgG immunocomplexes were isolated from a high molecular fraction, IgM anti- beta 2-glycoprotein I and anticardiolipin antibodies were detected. Thus IgG, IgM ad IgG-IgM complexes of anti-beta 2-glycoprotein I antibodies are present at the same time in a patient with antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608682     DOI: 10.1007/bf02207930

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

2.  Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.

Authors:  E Matsuura; Y Igarashi; M Fujimoto; K Ichikawa; T Koike
Journal:  Lancet       Date:  1990-07-21       Impact factor: 79.321

3.  The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants.

Authors:  P Thiagarajan; V Pengo; S S Shapiro
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

4.  Serum of normal subjects contains IgG with antibody-like specificity for phospholipids.

Authors:  V Pengo; A Ruffati; A Baritussio; L de Marco; S Todesco; A Girolami
Journal:  Folia Haematol Int Mag Klin Morphol Blutforsch       Date:  1984

5.  Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis.

Authors:  A Biasiolo; V Pengo
Journal:  Blood Coagul Fibrinolysis       Date:  1993-06       Impact factor: 1.276

6.  Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions.

Authors:  E Polz; H Wurm; G M Kostner
Journal:  Int J Biochem       Date:  1980

7.  Antiphospholipid cofactor.

Authors:  A E Gharavi
Journal:  Stroke       Date:  1992-02       Impact factor: 7.914

8.  Immunological specificity and mechanism of action of IgG lupus anticoagulants.

Authors:  V Pengo; P Thiagarajan; S S Shapiro; M J Heine
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

9.  Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I.

Authors:  R A Roubey; C W Pratt; J P Buyon; J B Winfield
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Anticardiolipin antibodies and dependence of a serum cofactor. A mechanism of thrombosis.

Authors:  J Ordi; A Selva; F Monegal; J M Porcel; X Martinez-Costa; M Vilardell
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

View more
  1 in total

1.  Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome.

Authors:  Laura Naranjo; Ljudmila Stojanovich; Aleksandra Djokovic; Laura Andreoli; Angela Tincani; Maria Maślińska; Savino Sciascia; Maria Infantino; Sara Garcinuño; Kinga Kostyra-Grabczak; Mariangela Manfredi; Francesca Regola; Natasa Stanisavljevic; Milomir Milanovic; Jovica Saponjski; Dario Roccatello; Irene Cecchi; Massimo Radin; Maurizio Benucci; Daniel Pleguezuelo; Manuel Serrano; Yehuda Shoenfeld; Antonio Serrano
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.